Free Trial

Point72 Asset Management L.P. Purchases 1,858,440 Shares of Xencor, Inc. (NASDAQ:XNCR)

Xencor logo with Medical background

Point72 Asset Management L.P. increased its position in Xencor, Inc. (NASDAQ:XNCR - Free Report) by 147.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,120,229 shares of the biopharmaceutical company's stock after purchasing an additional 1,858,440 shares during the quarter. Point72 Asset Management L.P. owned approximately 4.46% of Xencor worth $62,748,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in XNCR. Linden Thomas Advisory Services LLC lifted its holdings in shares of Xencor by 1.6% during the second quarter. Linden Thomas Advisory Services LLC now owns 43,643 shares of the biopharmaceutical company's stock valued at $826,000 after purchasing an additional 699 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Xencor during the 2nd quarter valued at about $154,000. Diversified Trust Co increased its stake in Xencor by 7.8% during the 2nd quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company's stock valued at $266,000 after purchasing an additional 1,017 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Xencor by 3.0% in the second quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company's stock worth $587,000 after buying an additional 900 shares in the last quarter. Finally, Baillie Gifford & Co. grew its holdings in shares of Xencor by 3.3% during the second quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company's stock valued at $445,000 after buying an additional 744 shares during the last quarter.

Xencor Stock Performance

Shares of Xencor stock traded down $0.88 on Thursday, hitting $25.32. 934,076 shares of the company's stock were exchanged, compared to its average volume of 610,362. Xencor, Inc. has a 1 year low of $15.31 and a 1 year high of $27.24. The company has a 50-day simple moving average of $22.41 and a 200-day simple moving average of $20.63. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The stock has a market capitalization of $1.77 billion, a PE ratio of -7.91 and a beta of 0.69.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $10.70 million during the quarter, compared to analyst estimates of $14.59 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. Xencor's revenue for the quarter was down 81.9% on a year-over-year basis. As a group, equities analysts anticipate that Xencor, Inc. will post -3.71 EPS for the current year.

Insider Buying and Selling

In other Xencor news, Director Alan Bruce Montgomery sold 1,421 shares of the firm's stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total transaction of $38,409.63. Following the sale, the director now directly owns 9,140 shares of the company's stock, valued at $247,054.20. This trade represents a 13.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP John R. Desjarlais sold 68,684 shares of the company's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $23.48, for a total value of $1,612,700.32. Following the completion of the transaction, the vice president now directly owns 200,104 shares of the company's stock, valued at approximately $4,698,441.92. This trade represents a 25.55 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,050 shares of company stock valued at $3,277,609. 5.23% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on XNCR. JPMorgan Chase & Co. upped their price objective on Xencor from $27.00 to $28.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Royal Bank of Canada lifted their price objective on Xencor from $31.00 to $34.00 and gave the stock an "outperform" rating in a report on Thursday, September 26th. Piper Sandler upgraded shares of Xencor from a "neutral" rating to an "overweight" rating and upped their target price for the company from $20.00 to $30.00 in a research note on Monday. BMO Capital Markets reissued an "outperform" rating and set a $34.00 price objective (up from $32.00) on shares of Xencor in a report on Friday, November 8th. Finally, Wedbush restated an "outperform" rating and issued a $38.00 target price on shares of Xencor in a report on Thursday, November 7th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $36.50.

Get Our Latest Stock Report on Xencor

Xencor Company Profile

(Free Report)

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Featured Stories

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Should you invest $1,000 in Xencor right now?

Before you consider Xencor, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xencor wasn't on the list.

While Xencor currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines